Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 4

Aspirin direnci: Şimdi biz neredeyiz?

Aspirin resistance: Where are we now?

Pages
370–373
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article summarizes aspirin resistance, discussing its definition, clinical outcomes, laboratory tests, possible causes and therapeutic approaches.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events.
📊
Key Findings & Data:However, clinical and laboratory evidence demon- strates diminished or no response to aspirin in some patients that is called aspirin resistance.
💡
Conclusion & Impact:This article summarizes aspirin resistance, discussing its definition, clinical outcomes, laboratory tests, possible causes and therapeutic approaches.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events. However, clinical and laboratory evidence demon- strates diminished or no response to aspirin in some patients that is called aspirin resistance. This situation has been reported to be indepen- dently associated with an increased risk of adverse cardiovascular events. The exact mechanism of aspirin resistance has not been established yet. The clinical, pharmacological and genetic factors may be associated with aspirin resistance. However, there is not currently standardized test to the diagnosis and no proven effective treatment of aspirin resistance. This article summarizes aspirin resistance, discussing its definition, clinical outcomes, laboratory tests, possible causes and therapeutic approaches.

Özet

Trombo-embolik vasküler olayların engellenmesinde aspirin etkili bir antiplatelet ilaçtır. Bununla beraber bazı hastaların klinik ve laboratuvar bulguları aspirine cevabın azalmış veya hiç olmadığını gösterir. Bu durum aspirin direnci olarak adlandırılır ve artmış kardiyovasküler risk ile ilişkili olduğu bildirilmiştir. Aspirin direncinin mekanizması henüz tam olarak ortaya konulmamıştır. Klinik, farmakolojik ve genetik faktörler aspi- rin direnci ile ilişkili olabilir. Bununla birlikte aspirin direncinin günümüzde tanı için standardize testi ve kanıtlamış tedavisi yoktur. Bu makale aspirin direncini tanımlama, klinik sonuçlar, laboratuvar testleri, olası nedenler ve tedavisel yaklaşımları tartışarak özetlemiştir.

🔖

Cite This Article

ABACI, O., ORTA, K. K. (2022). Aspirin direnci: Şimdi biz neredeyiz?. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 4, 370–373. https://ajindex.com/articles/436600

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet ther- apy in various categories of patients. BMJ 1994
  2. [CrossRef] 2. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006
  3. [CrossRef] 3. Tantry US, Bliden KP Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005
  4. [CrossRef] 4. Brunton L, Lazo J, Parker K. Goodman and Gilman‘s The Pharmacological basis of Therapeutics. New York
  5. McGraw-Hill Professional. 2005. 5. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006
  6. [CrossRef] 6. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008
  7. [CrossRef] 7. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007
  8. [CrossRef] 8. Cattaneo M. Resistance to antiplatelet drugs: molecular mecha- nisms and laboratory detection. J Thromb Haemost 2007
  9. [CrossRef] 9. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004
  10. [CrossRef] 10. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005
  11. [CrossRef] 11. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001
  12. [CrossRef] 12. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005
  13. [CrossRef] 13. Friend M, Vucenik I, Miller M. Research pointers: Platelet respon- siveness to aspirin in patients with hyperlipidaemia. BMJ 2003
  14. [CrossRef] 14. Kılıçkesmez KO, Koçaş C, Ökçün B, Abacı O, Kaya A, Arat A, et al. Laboratory signs of aspirin response in haemodialysis patients. Scand J Clin L